Ribo's Vortosiran Shows Strong FXI Inhibition in Phase 2a Trial for Coronary Artery Disease
Event summary
- Ribo's Phase 2a trial of vortosiran in chronic coronary artery disease patients showed a mean maximum reduction in FXI activity of 92% with a maintenance dose of 400mg.
- The study was randomized, double-blind, and placebo-controlled, demonstrating that vortosiran was generally well tolerated with no treatment-related serious adverse events or major bleeding events observed.
- Vortosiran's FXI inhibition is markedly greater than that estimated for ongoing small molecule programs in Phase 3 development.
- Ribo has initiated the ORBIT-XI program, including several Phase 2b trials designed to support rapid progression into Phase 3 development across multiple indications.
The big picture
Ribo's positive Phase 2a data for vortosiran represents a significant milestone in the development of siRNA-mediated FXI inhibition for cardiovascular diseases. The ability to achieve profound and sustained FXI suppression without increasing bleeding risk addresses a major unmet need in anticoagulant therapy. This advancement positions Ribo competitively in the growing market for innovative antithrombotic treatments, potentially offering a safer and more effective alternative to existing therapies.
What we're watching
- Clinical Progression
- The pace at which Ribo advances vortosiran through Phase 2b and into Phase 3 trials will determine its market potential.
- Competitive Positioning
- Whether vortosiran's superior FXI inhibition can differentiate it from small molecule programs in development.
- Safety Profile
- How the long-term safety and efficacy of vortosiran will be established in broader patient populations.
Related topics